# Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

> **NCT05193292** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 77 (estimated)

## Conditions studied

- Colorectal Neoplasms
- Intestinal Neoplasms

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Trastuzumab
- **DRUG:** XELOX regimen
- **DRUG:** mFOLFOX6 regimen
- **DRUG:** FOLFIRI regimen
- **DRUG:** mXELIRI regimen
- **DRUG:** mIRIS regimen

## Key facts

- **NCT ID:** NCT05193292
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01
- **Primary completion:** 2024-01
- **Final completion:** 2025-01
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05193292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05193292, "Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05193292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*